MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.bneo.2026.100243

Медицинская библиотека · Blood neoplasia · 2026

Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R/R MDS.

Jang H Josh, Urrutia Guillermo, Ørskov Andreas Due, Nguyen Anh Van, Kim Hyeon Jin, Nelson Seth A, Lee Hyein, Burgos Ryan S, Johnson Benjamin K, Wegener Marc, Becker Katelyn, Adams Marie, Sheridan Rachael, Ramjan Zachary H, Givan Scott A, Zebley Caitlin C, Youngblood Benjamin A, Issa Jean-Pierre J, Topper Michael J, Baylin Stephen B, Baer Maria R, Triche Timothy J, O'Connell Casey L, Grønbæk Kirsten, Jones Peter A

СтатьяПеревод пока не подготовлен

Аннотация

Approximately half of patients with myelodysplastic syndromes (MDS) relapse or are refractory to hypomethylating agents (HMAs) and experience poor clinical outcomes. We previously reported improved survival in a phase 1/2 clinical trial combining the HMA guadecitabine with a programmed death-ligand 1 (PD-L1) inhibitor (atezolizumab) in HMA-relapsed or HMA-refractory (HMA-R/R) MDS, yet the biological features associated with durable responses to this combined epigenetic and immunotherapy approach remain unclear. Here, we performed integrated bulk and single-cell transcriptomic profiling of bone marrow samples from patients treated on this trial to identify molecular and cellular features associated with survival. Long-term survival was associated with the presence of immunosuppressive myeloid cells and primed dendritic cells at baseline, together with therapy-induced immune reinvigoration characterized by interferon pathway activation and expansion of effector lymphocytes. In contrast, short-term survival was associated with persistent senescence-associated inflammatory programs in CD34+ bone marrow cells and elevated expression of immunosuppressive immune checkpoint molecules. These findings suggest that chronic inflammatory and senescent microenvironmental states constrain effective immune activation despite combined epigenetic and immune checkpoint therapy. Here, we identify distinct bone marrow microenvironments associated with patient survival after combined epigenetic and immune checkpoint therapy and suggest candidate biomarkers to guide patient stratification in HMA-R/R MDS.

Для цитирования: Jang H Josh, Urrutia Guillermo, Ørskov Andreas Due, Nguyen Anh Van, Kim Hyeon Jin, Nelson Seth A, Lee Hyein, Burgos Ryan S, Johnson Benjamin K, Wegener Marc, Becker Katelyn, Adams Marie, Sheridan Rachael, Ramjan Zachary H, Givan Scott A, Zebley Caitlin C, Youngblood Benjamin A, Issa Jean-Pierre J, Topper Michael J, Baylin Stephen B, Baer Maria R, Triche Timothy J, O'Connell Casey L, Grønbæk Kirsten, Jones Peter A. Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R/R MDS.. Blood neoplasia. 2026. DOI: 10.1016/j.bneo.2026.100243.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.